[1] |
Zheng XH, Jia B, Lin X, et al. FRMD4A: A potential therapeutic target for the treatment of tongue squamous cell carcinoma[J]. Int J Mol Med, 2016, 38(5): 1443-1449.
doi: 10.3892/ijmm.2016.2745
pmid: 27666346
|
[2] |
Ibarra AMC, Garcia MP, Ferreira M, et al. Effects of photobiomodulation on cellular viability and cancer stem cell phenotype in oral squamous cell carcinoma[J]. Lasers Med Sci, 2021, 36(3): 681-690.
|
[3] |
Kuroda K, Yashiro M, Sera T, et al. The clinicopathological significance of thrombospondin-4 expression in the tumor microenvironment of gastric cancer[J]. PLoS One, 2019, 14(11): e0224727.
|
[4] |
Sacco AG, Cohen EE. Current treatment options for recurrent or metastatic head and neck squamous cell carcinoma[J]. J Clin Oncol, 2015, 33(29): 3305-3313.
doi: 10.1200/JCO.2015.62.0963
pmid: 26351341
|
[5] |
Podojil JR, Miller SD. Potential targeting of B7-H4 for the treatment of cancer[J]. Immunol Rev, 2017, 276(1): 40-51.
doi: 10.1111/imr.12530
pmid: 28258701
|
[6] |
Carvajal-Hausdorf D, Altan M, Velcheti V, et al. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)[J]. J Immunother Cancer, 2019, 7(1): 65.
doi: 10.1186/s40425-019-0540-1
pmid: 30850021
|
[7] |
Cheng HY, Borczuk A, Janakiram M, et al. Wide expression and significance of alternative immune checkpoint molecules, B7x and HHLA2, in PD-L1-negative human lung cancers[J]. Clin Cancer Res, 2018, 24(8): 1954-1964.
doi: 10.1158/1078-0432.CCR-17-2924
pmid: 29374053
|
[8] |
Dong LJ, Xie LL, Li MJ, et al. Downregulation of B7-H4 suppresses tumor progression of hepatocellular carcinoma[J]. Sci Rep, 2019, 9(1): 14854.
doi: 10.1038/s41598-019-51253-2
pmid: 31619714
|
[9] |
Wang XL, Wang S, Wu ZZ, et al. Overexpression of ATAD2 indicates poor prognosis in oral squamous cell carcinoma[J]. Int J Med Sci, 2020, 17(11): 1598-1609.
|
[10] |
高永强, 施鹏伟, 刘晓晓, 等. MiR-126在口腔鳞状细胞癌组织中的表达及其临床意义[J]. 中国肿瘤生物治疗杂志, 2021, 28(1): 48-54.
|
[11] |
Santosh N, McNamara KK, Beck FM, et al. Expression of cornulin in oral premalignant lesions[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2019, 127(6): 526-534.
|
[12] |
Ogłuszka M, Orzechowska M, Jędroszka D, et al. Evaluate Cutpoints: Adaptable continuous data distribution system for determining survival in Kaplan-Meier estimator[J]. Comput Methods Programs Biomed, 2019, 177: 133-139.
|
[13] |
Lenze NR, Farquhar DR, Dorismond C, et al. Age and risk of recurrence in oral tongue squamous cell carcinoma: Systematic review[J]. Head Neck, 2020, 42(12): 3755-3768.
|
[14] |
Okuyama K, Suzuki K, Yanamoto S, et al. Anaplastic transition within the cancer microenvironment in early-stage oral tongue squamous cell carcinoma is associated with local recurrence[J]. Int J Oncol, 2018, 53(4): 1713-1720.
doi: 10.3892/ijo.2018.4515
pmid: 30085337
|
[15] |
Gao F, Li C, Zhao XQ, et al. CKS2 modulates cell-cycle progression of tongue squamous cell carcinoma cells partly via modulating the cellular distribution of DUTPase[J]. J Oral Pathol Med, 2021, 50(2): 175-182.
doi: 10.1111/jop.13116
pmid: 33107644
|
[16] |
Cohen EEW, Soulières D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): A randomised, open-label, phase 3 study[J]. Lancet, 2019, 393(10167): 156-167.
doi: S0140-6736(18)31999-8
pmid: 30509740
|
[17] |
Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression[J]. Oral Oncol, 2018, 81: 45-51.
doi: S1368-8375(18)30149-0
pmid: 29884413
|
[18] |
Segal NH, Ou SI, Balmanoukian A, et al. Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: Results from a phase I/II expansion cohort[J]. Eur J Cancer, 2019, 109: 154-161.
doi: S0959-8049(19)30007-3
pmid: 30731276
|
[19] |
Akisada N, Nishimoto K, Takao S, et al. PD-L1 expression in tongue squamous cell carcinoma[J]. Med Mol Morphol, 2021, 54(1): 52-59.
|
[20] |
John P, Wei Y, Liu WF, et al. The B7x immune checkpoint pathway: From discovery to clinical trial[J]. Trends Pharmacol Sci, 2019, 40(11): 883-896.
doi: S0165-6147(19)30226-3
pmid: 31677920
|
[21] |
Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint[J]. Immunity, 2018, 48(3): 434-452.
doi: S1074-7613(18)30090-6
pmid: 29562194
|
[22] |
Niu N, Shen WW, Zhong YP, et al. Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas[J]. Hum Pathol, 2021, 113: 20-27.
doi: 10.1016/j.humpath.2021.04.003
pmid: 33887301
|
[23] |
Chen LY, Dong JF, Li ZY, et al. The B7H4-PDL1 classifier stratifies immuno-phenotype in cervical cancer[J]. Cancer Cell Int, 2022, 22(1): 3.
doi: 10.1186/s12935-021-02423-8
pmid: 34983532
|
[24] |
Wu L, Deng WW, Yu GT, et al. B7-H4 expression indicates poor prognosis of oral squamous cell carcinoma[J]. Cancer Immunol Immunother, 2016, 65(9): 1035-1045.
doi: 10.1007/s00262-016-1867-9
pmid: 27383830
|